news

Our latest
Press Releases & Updates

Latest press releases

RetinAI’s technology accelerated large-scale analysis of fluid dynamics in a Real-World, neovascular Age-related Macular Degeneration (nAMD) national database

RetinAI is proud to have provided its CE-marked AI tools for fluid quantification to support the analysis in a large scale, multicenter, real-world national database of neovascular Age related Macular Degeneration (nAMD) patients. The results of the study, recently published in the British Journal of Ophthalmology, demonstrate that volumetric measures derived from AI-based segmentation of OCT volumes provide useful information for clinicians to consult their patients at diagnosis.

RetinAI launches Discovery CORE™: an AI-powered, collaborative platform to accelerate Clinical & Academic Research, & RWE analysis in ophthalmology

RetinAI is proud to launch Discovery CORE™ with AI for retinal fluid and layer segmentation. Discovery CORE and its AI models have been designed to accelerate data analysis and help clinical and academic researchers collaborate more efficiently, in real time, with their peers, on medical and imaging datasets. Automatically and in an instant, the software measures retinal fluid volumes and retinal layer thickness across OCT datasets. With built-in annotation tools and electronic case report forms, new data insights can also be collected across peer networks, keeping the information digitized, centralized and secure.

RetinAI will attend AAO 2022 & is excited to introduce advances in AI for GA analysis & Progression Prediction & Discovery CORE™

RetinAI is a leader in clinical and imaging data management software and advanced analytics for Ophthalmology. The company’s platform technology and AI improve workflows in research, clinical studies and bring precision medicine applications to pharma, clinical research organizations (CROs) and clinicians.

RetinAI Expands Operations to Set Up a U.S. Office In Boston and Achieves 21 CFR Part 11 Compliance to Support Research and Clinical Studies

RetinAI, a leader in clinical and imaging data management software and advanced analytics for ophthalmology, is excited to announce the launch of its first U.S.-based office, located in Boston, MA. This expansion will support further growth within the U.S. market, building upon existing collaborations with U.S.-based pharmaceutical companies and its partnership with Heidelberg Engineering to distribute RetinAI’s Disease AI Apps for research use in the U.S. The Boston office will be RetinAI’s second location, in addition to its Bern headquarters.

RetinAI in RTS- Swiss television

The last week of August we received the Swiss Television (SRF - Schweizer Radio und Fernsehen) at our offices in Bern.We talked for a few minutes about what we do and how artificial intelligence is going to change ophthalmology and healthcare in the near future!
‍
Watch it here

Arvo 2019 - Vancouver [MAY’19]

RetinAI had a great conference at this year at ARVO 2019, with more than 15’000 attendees from all over the world!Congratulations to the team for these amazing 5 days of work and for the success on the official release of our two main products: OmniViewer and RetinAI Discovery.

Democratising Access to Health Care - INVESTIERE [APRIL’19]

"Automation does not replace jobs, it replaces tasks" - Learn how RetinAI applies machine learning to medical imaging, not to replace eye doctors, but to make their work less tedious. Via Investiere Venture Capital - Read more

RetinAI in FORBES FR [DECEMBER’18]

RetinAI is honoured to be in December's edition of Forbes France! Artificial Intelligence is changing the world of ophthalmology by democratising access to high-quality eye-care for everyone. Discover a bit more about the future of healthcare in 2019, starting with your eyes! [FR]

‍

Our latest
Press Releases & Updates

Latest press releases

RetinAI’s technology accelerated large-scale analysis of fluid dynamics in a Real-World, neovascular Age-related Macular Degeneration (nAMD) national database

RetinAI launches Discovery CORE™: an AI-powered, collaborative platform to accelerate Clinical & Academic Research, & RWE analysis in ophthalmology

RetinAI will attend AAO 2022 & is excited to introduce advances in AI for GA analysis & Progression Prediction & Discovery CORE™

RetinAI Expands Operations to Set Up a U.S. Office In Boston and Achieves 21 CFR Part 11 Compliance to Support Research and Clinical Studies

Latest updates

RetinAI in RTS- Swiss television

Arvo 2019 - Vancouver [MAY’19]

Democratising Access to Health Care - INVESTIERE [APRIL’19]

RetinAI in FORBES FR [DECEMBER’18]

Contact us for more informations! We are happy to hear from you!

Sign Up And Receive Our Latest Promotions!

Our latest Press Releases & Updates

Latest press releases

RetinAI’s technology accelerated large-scale analysis of fluid dynamics in a Real-World, neovascular Age-related Macular Degeneration (nAMD) national database

RetinAI launches Discovery CORE™: an AI-powered, collaborative platform to accelerate Clinical & Academic Research, & RWE analysis in ophthalmology

RetinAI will attend AAO 2022 & is excited to introduce advances in AI for GA analysis & Progression Prediction & Discovery CORE™

RetinAI Expands Operations to Set Up a U.S. Office In Boston and Achieves 21 CFR Part 11 Compliance to Support Research and Clinical Studies

Latest updates

RetinAI in RTS- Swiss television

Arvo 2019 - Vancouver [MAY’19]

Democratising Access to Health Care - INVESTIERE [APRIL’19]

RetinAI in FORBES FR [DECEMBER’18]

Contact us for more informations! We are happy to hear from you!

Our latest
Press Releases & Updates